Use of the Collagen Gel Droplet Embedded Drug Sensitivity Test to Determine Drug Sensitivity against Ovarian Mature Cystic Teratoma with Malignant Transformation to Adenocarcinoma: A Case Report

Abstract

Background: The collagen gel droplet embedded drug sensitivity test (CD-DST) is a new anticancer drug sensitivity test that only requires a small number of cells. We report the use of this test in the choice of adjuvant chemotherapy for treatment of a rare case of ovarian cancer involving malignant transformation of ovarian mature cystic teratoma. Case Report: The patient was a 70-year-old female with an ovarian tumor, pleural effusion, carcinomatous ascites and a chest wall tumor. The histopathological diagnosis was adenocarcinoma, mature cystic teratoma with malignant transformation, stage IV. Paclitaxel/carboplatin therapy was selected as adjuvant chemotherapy based on CD-DST results. Upon completion of 6 courses, no increases in carcinomatous ascites or recurrent lesions were evident, and the chest wall tumor had disappeared completely. Conclusion: The CD-DST may be particularly useful for selecting preoperative chemotherapeutic drugs for patients with ovarian cancer in which the histological type of the primary tumor is unknown.

Synovial sarcoma individual chemotherapy directed by collagen gel droplet embedded culture drug sensitivity test: A case report

“…The collagen gel droplet embedded culutre-drug sensitivity test (CD-DST) is an anticancer drug sensitivity test that requires only a small number of cells (3x10 3 per droplet) (2-4). The clinical usefulness of CD-DST for colon (5), breast (6) and gastric (7) cancers and even certain rare cases of solid tumors, such as ovarian mature cystic teratoma with malignant transformation to adenocarcinoma (8), have been reported. Yabushita et al (9) found a strong correlation between clinical outcome and CD-DST results for anticancer drugs.…”